Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Cytarabine 272Cyclophosphamide 136fludarabine phosphate 127Azacitidine 117Peripheral Blood Stem Cell Transplantation 95Busulfan 93Filgrastim 80Decitabine 79fludarabine 78Mycophenolic Acid 78Idarubicin 76Etoposide 76Whole-Body Irradiation 75Daunorubicin 72Tacrolimus 71Cyclosporine 64Methotrexate 62Mitoxantrone 57Clofarabine 55Antilymphocyte Serum 55Granulocyte Colony-Stimulating Factor 51Gemtuzumab 50Melphalan 49venetoclax 48Radiotherapy 30sargramostim 28Injections 25Bortezomib 25thymoglobulin 24aldesleukin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid, Acute × merestinib × Clear all
NCT03125239 2020-06-30

Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia

Dana-Farber Cancer Institute

Phase 1 Completed
16 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡